Ebola & Marburg Virus

Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by human-to-human transmission via direct contact or contact with infected bodily fluids or contaminated fomites. EVD has a high case–fatality rate; it is characterized by fever, gastrointestinal signs and multiple organ dysfunction syndrome.(1) antibodies-online supports research on EBOV and MARV with a wide range of high-quality antibodies, proteins.

Marburg and Ebola Viruses: Disease Classification and Evolution

Marburgvirus (MARV) is closely related to the better-known Ebola virus and causes a similarly severe disease in humans. Some of the unique characteristics of filovirus outbreaks were reported for MARV disease (MVD) long before they were noticed in EBOV disease. (8) A likely natural host for MARV and RAVV, and the probable source of the highly infectious viruses that cause Marburg virus disease (MVD) in humans, is the Egyptian fruit bat (Rousettus aegyptiacus).(9)

Marburg virus and Ebola virus belong to the family Filoviridae. To date, 12 distinct filoviruses have been described. The seven filoviruses that have been found in humans belong either to the genus Ebolavirus (Bundibugyo virus (BDBV), Ebola virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV) and Taï Forest virus (TAFV)) or to the genus Marburgvirus (Marburg virus (MARV) and Ravn virus (RAVV))(Fig 1). The WHO International Classification of Diseases Revision 11 of 2018 recognizes two major subcategories of filovirus disease (FVD): Ebola disease caused by BDBV, EBOV, SUDV or TAFV, and Marburg disease caused by MARV or RAVV.(1)

Genome Organization of Ebola Virus and Marburg Virus

The 19 kb viral genome encodes for seven main proteins: nucleoprotein (NP), glycoprotein (GP), L-polymerase (L) protein, viral protein (VP) 24, VP30, VP35, and VP40 (Fig 2). L is an RNA-dependent RNA polymerase (RdRp) and forms the RdRp complex with VP30 that is responsible for viral genome transcription and replication. VP24 and VP35 inhibit interferon signalling and facilitate evasion of the host immune response. NP encapsidates the viral genome into the nucleocapsid, whilst VP40 drives viral assembly and budding. GP is the only protein on the surface of the virion and is essential for binding to target cells and subsequently mediating membrane fusion and the release of the viral genome.(11)

Monoclonal Antibodies and Biosimilars in Ebola Treatment

Before 2014, almost all Ebola pipeline candidates were at the pre-clinical stage. Today, following a coordinated global effort, there are active pipelines for diagnostics, drugs and vaccines, with multiple candidates in late-stage clinical development. In 2018, the WHO approved five experimental therapies – three monoclonal antibodies (ZMapp, mAb114 and REGN-EB3) and two antiviral drugs (remdesivir and favipiravir) – for the treatment of Ebola under the MEURI protocol (adopted for the first time ever).(4) The first-ever multi-drug trial investigating the efficacy of these drugs (other than favipiravir) began in 2018.(5)(6) In 2019, mAb114 and REGN-EB3 were deemed superior to ZMapp and both received Breakthrough Therapy designation from the FDA.(5)(6)

Biosimilars for Zaire Ebola Virus

Following the 2018–2019 PALM trial in the Democratic Republic of the Congo, monoclonal antibody therapies demonstrated clear survival benefit, leading to regulatory approvals for Inmazeb (REGN-EB3) and Ebanga (ansuvimab/mAb114) for Ebola virus disease caused by Zaire ebolavirus. Post-approval efforts have focused on optimizing early administration, improving manufacturing scalability, and evaluating combination strategies to enhance efficacy in resource-limited outbreak settings. In parallel, research has expanded toward next-generation monoclonal antibodies with broader neutralization breadth and small-molecule antivirals targeting conserved filoviral proteins. Despite progress, the development of a pan-filovirus therapeutic active against multiple Ebolavirus and Marburgvirus species remains a central objective in the field.(7)

Antibodies for Ebola & Marburg Virus Research

antibodies-online offers the following research antibodies for laboratory research on Ebola and Marburg virus. For more details click on the product links below. In case of any question do not hesitate to contact our scientific customer support.

Bundibugyo Ebola Virus Proteins

Bundibugyo Ebola Virus Antibodies